Turner Syndrome Clinical Trial
Official title:
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy
Several studies have demonstrated that Turner Syndrome patients have elevated liver enzymes readily suppressible by a short course of HRT. We wanted to estimated quantitative liver functions in a young group of Turner syndrome patients compared to a healthy control group.
Turner syndrome is due to the absence of a part of or the entire X chromosome in females.
Stature is short, and morbidity is increased due to risk of osteoporosis and fractures, type
2 diabetes, ischemic heart disease, hypertension, and stroke, but also the risk of cirrhosis
is increased. Clinical studies have shown a frequent occurrence of elevated liver enzymes,
primarily alanine aminotransferase, g-glutamyl-transferase, and alkaline phosphatase, while
bilirubin is normal.
We and others have shown a normalizing effect of hormone replacement therapy (HRT),
containing 17bestradiol and a gestagen, on liver enzymes, which may point towards a
protective effect on hepatocyte integrity. Marked architectural changes, including nodular
regenerative hyperplasia, multiple focal nodular hyperplasia and cirrhosis are observed in
some patients and are associated with a risk of liver-related complications. These changes
are frequently associated with vascular disorders such as obliterative portal venopathy,
probably related to congenitally abnormal vessels. Steatosis, steatofibrosis, and
steatohepatitis are seen and may be caused by metabolic disorders. In addition, bile duct
alterations resembling small duct sclerosing cholangitis are observed in several patients.
Presently, it is not known whether these perturbations in liver morphology and in
liver-derived enzymes are related to functional defects in females with TS and whether this
may change by HRT. To further explore quantitative liver function in TS, we examined adult
women with TS on and off HRT and compared them with a control group of age matched normal
women. We used the galactose elimination capacity to assess hepatocyte cytosol activity, the
plasma clearance of indocyanine green to assess hepatic blood flow and excretory liver cell
function independently of hepatic blood flow, the antipyrine plasma clearance to estimate
hepatic microsomal system activity, and the functional hepatic nitrogen clearance to assess
mitochondrial- cytosolic metabolic capacity for conversion of amino-nitrogen.We assumed that
one or more these metabolic liver functions would be diminished in untreated TS and
normalized by HRT. Our principal objective was to understand mechanistically how HRT
improves liver function in TS.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
| Completed |
NCT01678261 -
X-chromosome Inactivation, Epigenetics and the Transcriptome
|
N/A | |
| Completed |
NCT01419249 -
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
|
Phase 4 | |
| Completed |
NCT01518036 -
Use of Somatropin in Turner Syndrome
|
Phase 3 | |
| Recruiting |
NCT04948658 -
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
|
||
| Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT02787486 -
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
|
||
| Completed |
NCT00877942 -
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome
|
N/A | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
| Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
| Completed |
NCT01322165 -
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
|
N/A | |
| Terminated |
NCT00419107 -
Beta Cell Function in Women With Turner Syndrome
|
N/A | |
| Active, not recruiting |
NCT00625001 -
Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
|
N/A | |
| Completed |
NCT00029159 -
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome
|
Phase 3 | |
| Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
| Completed |
NCT00471731 -
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
|
N/A | |
| Completed |
NCT00256126 -
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
|
Phase 4 | |
| Completed |
NCT03181230 -
Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome
|
||
| Completed |
NCT02160717 -
Risk of Diabetes in Young Turner Syndrome Patients
|
N/A |